NASDAQ:BGLC - Nasdaq - US0906282076 - Common Stock - Currency: USD
NASDAQ:BGLC (2/21/2025, 8:03:18 PM)
0.3513
+0.01 (+2.72%)
The current stock price of BGLC is 0.3513 USD. In the past month the price increased by 2.03%. In the past year, price decreased by -48.35%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
GWW | WW GRAINGER INC | 25.87 | 49.08B | ||
URI | UNITED RENTALS INC | 15.2 | 43.13B | ||
FAST | FASTENAL CO | 37.2 | 42.88B | ||
FERG | FERGUSON ENTERPRISES INC | 18.55 | 35.19B | ||
WSO.B | WATSCO INC -CL B | 38.63 | 23.51B | ||
WSO | WATSCO INC | 37.64 | 22.90B | ||
AER | AERCAP HOLDINGS NV | 8.6 | 19.29B | ||
FTAI | FTAI AVIATION LTD | 48.25 | 13.26B | ||
CNM | CORE & MAIN INC-CLASS A | 22.06 | 10.13B | ||
AIT | APPLIED INDUSTRIAL TECH INC | 24.89 | 9.43B | ||
WCC | WESCO INTERNATIONAL INC | 14.95 | 8.98B | ||
BECN | BEACON ROOFING SUPPLY INC | 16.11 | 7.22B |
BioNexus Gene Lab Corp. is a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The firm provides a molecular lab that is focused on the application of functional genomics to enable early detection of infectious diseases and cancers. The firm operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex. MRNA Scientific Malaysia owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which the Company uses in its business. The firm's non-invasive blood screening tests analyze changes in RNA to coronavirus, dengue, human immunodeficiency virus (HIV), human papillomavirus (HPV) and the risk potentiality of cancer diseases. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asean region.
BIONEXUS GENE LAB CORP
10-2 Tower B, Vertical Business Suite, 8 Jalan Kerinchi
KUALA LUMPUR WILAYAH PERSEKUTUAN MY
Employees: 9
Company Website: https://www.bionexusgenelab.com/
Investor Relations: http://www.bionexusgenelab.com/investor-relation
Phone: 13072416898
The current stock price of BGLC is 0.3513 USD. The price increased by 2.72% in the last trading session.
The exchange symbol of BIONEXUS GENE LAB CORP is BGLC and it is listed on the Nasdaq exchange.
BGLC stock is listed on the Nasdaq exchange.
BIONEXUS GENE LAB CORP (BGLC) has a market capitalization of 6.31M USD. This makes BGLC a Nano Cap stock.
BIONEXUS GENE LAB CORP (BGLC) currently has 9 employees.
BIONEXUS GENE LAB CORP (BGLC) has a support level at 0.34 and a resistance level at 0.36. Check the full technical report for a detailed analysis of BGLC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BGLC does not pay a dividend.
BIONEXUS GENE LAB CORP (BGLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
The outstanding short interest for BIONEXUS GENE LAB CORP (BGLC) is 3.1% of its float. Check the ownership tab for more information on the BGLC short interest.
ChartMill assigns a technical rating of 3 / 10 to BGLC. When comparing the yearly performance of all stocks, BGLC is a bad performer in the overall market: 80.47% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to BGLC. No worries on liquidiy or solvency for BGLC as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months BGLC reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 77.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -8.57% | ||
ROE | -10.04% | ||
Debt/Equity | 0 |